Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2019 | Original Article – Cancer Research

Melanoma tumour vasculature heterogeneity: from mice models to human

Authors: Vincent Pautu, Adélie Mellinger, Pauline Resnier, Elise Lepeltier, Ludovic Martin, Lise Boussemart, Franck Letournel, Catherine Passirani, Nicolas Clere

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2019

Abstract

Tumour angiogenesis is defined by an anarchic vasculature and irregularities in alignment of endothelial cells. These structural abnormalities could explain the variability in distribution of nanomedicines in various tumour models. Then, the main goal of this study was to compare and to characterize the tumour vascular structure in different mouse models of melanoma tumours (B16F10 and SK-Mel-28) and in human melanomas from different patients. Tumours were obtained by subcutaneous injection of 10⁶ B16F10 and 3.10⁶ SK-Mel-28 melanoma cells in C57BL/6 and nude mice, respectively. Tumour growth was evaluated weekly, while vasculature was analysed through fluorescent labelling via CD31 and desmin. Significant differences in tumour growth and mice survival were evidenced between the two melanoma models. A fast evolution of tumours was observed for B16F10 melanoma, reaching a tumour size of 100 mm³ in 7 days compared to SK-Mel-28 which needed 21 days to reach the same volumes. Important differences in vascularization were exposed between the melanoma models, characterized by a significant enhancement of vascular density and a significant lumen size for mice melanoma models compared to human. Immunostaining revealed irregularities in endothelium structure for both melanoma models, but structural differences of vasculature were observed, characterized by a stronger expression of desmin in SK-Mel-28 tumours. While human melanoma mainly develops capillaries, structural irregularities are also observed on the samples of this tumour model. Our study revealed an impact of cell type and tumour progression on the structural vasculature of melanoma, which could impact the distribution of drugs in the tumour environment.

Armulik A, Genove G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21:193–215. https://doi.org/10.1016/j.devcel.2011.07.001 CrossRefPubMed

Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102–111. https://doi.org/10.1016/j.gde.2004.12.005 CrossRefPubMed

Barenholz Y (2012) Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release 160:117–134. https://doi.org/10.1016/j.jconrel.2012.03.020 CrossRefPubMed

Bolkestein M, de Blois E, Koelewijn SJ, Eggermont AM, Grosveld F, de Jong M, Koning GA (2016) Investigation of factors determining the enhanced permeability and retention effect in subcutaneous Xenografts. J Nucl Med 57:601–607. https://doi.org/10.2967/jnumed.115.166173 CrossRefPubMed

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases Nature 407:249–257. https://doi.org/10.1038/35025220 CrossRefPubMed

Chan RC, Babbs CF, Vetter RJ, Lamar CH (1984) Abnormal response of tumor vasculature to vasoactive drugs. J Natl Cancer Inst 72:145–150. https://doi.org/10.1093/jnci/72.1.145 CrossRefPubMed

Choi YP, Shim HS, Gao MQ, Kang S, Cho NH (2011) Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett 307:62–71. https://doi.org/10.1016/j.canlet.2011.03.018 CrossRefPubMed

Clere N et al (2010) Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer 127:2279–2291. https://doi.org/10.1002/ijc.25234 CrossRefPubMed

Danciu C et al (2013) A characterization of four B16 murine melanoma cell sublines molecular fingerprint and proliferation behavior. Cancer Cell Int 13:75. https://doi.org/10.1186/1475-2867-13-75 CrossRefPubMedPubMedCentral

Danciu C et al (2015) Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin Int. J Exp Pathol 96:73–80. https://doi.org/10.1111/iep.12114 CrossRef

Danhier F (2016) To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 244:108–121. https://doi.org/10.1016/j.jconrel.2016.11.015 CrossRefPubMed

Danhier F et al (2015) Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. Int J Pharm 479:399–407. https://doi.org/10.1016/j.ijpharm.2015.01.009 CrossRefPubMed

Danquah MK, Zhang XA, Mahato RI (2011) Extravasation of polymeric nanomedicines across tumor vasculature Adv Drug Deliv Rev 63:623–639. https://doi.org/10.1016/j.addr.2010.11.005 CrossRefPubMed

De Bock K, De Smet F, Leite De Oliveira R, Anthonis K, Carmeliet P (2009) Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells. J Mol Med (Berl) 87:561–569. https://doi.org/10.1007/s00109-009-0482-z CrossRef

De Bock K, Cauwenberghs S, Carmeliet P (2011) Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21:73–79. https://doi.org/10.1016/j.gde.2010.10.008 CrossRefPubMed

Dudley AC (2012) Tumor endothelial cells Cold Spring. Harb Perspect Med 2:a006536. https://doi.org/10.1101/cshperspect.a006536 CrossRef

Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA (2013) Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol 72:417–427. https://doi.org/10.1007/s00280-013-2209-7 CrossRefPubMedPubMedCentral

Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18:884–901. https://doi.org/10.1016/j.devcel.2010.05.012 CrossRefPubMedPubMedCentral

Elder DE, Van Belle P, Elenitsas R, Halpern A, Guerry D (1996) Neoplastic progression and prognosis in melanoma Semin Cutan Med Surg 15:336–348. https://doi.org/10.1016/s1085-5629(96)80047-2 CrossRefPubMed

Fleming C, Morrissey S, Cai Y, Yan J (2017) γδ T cells: unexpected regulators of cancer development and progression Trends Cancer 3:561–570. https://doi.org/10.1016/j.trecan.2017.06.003 CrossRefPubMedPubMedCentral

Folkman J (2002) Role of angiogenesis in tumor growth and metastasis Semin Oncol 29:15–8 https://doi.org/10.1053/sonc.2002.37263 CrossRef

Hanahan D, Weinberg RA (2000) The hallmarks of cancer Cell 100:57–70. https://doi.org/10.1016/S0092-8674(00)81683-9 CrossRefPubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

Hansen S, Sørensen FB, Vach W, Grabau DA, Bak M, Rose C (2004) Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients Histopathology 44:428–436. https://doi.org/10.1111/j.1365-2559.2004.01848.x CrossRefPubMed

Hashizume H et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363–1380. https://doi.org/10.1016/s0002-9440(10)65006-7 CrossRefPubMedPubMedCentral

Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T (2013) Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release 172:12–21. https://doi.org/10.1016/j.jconrel.2013.06.039 CrossRefPubMed

Hori K, Suzuki M, Tanda S, Saito S, Shinozaki M, Zhang QH (1991) Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension Jpn. J Cancer Res 82:1309–1316. https://doi.org/10.1111/j.1349-7006.1991.tb01797.x CrossRef

Hori K, Saito S, Takahashi H, Sato H, Maeda H, Sato Y (2000) Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride Jpn J Cancer Res 91:261–269. https://doi.org/10.1111/j.1349-7006.2000.tb00940.x CrossRefPubMedPubMedCentral

Jain RK (2001) Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 74:7–25. https://doi.org/10.1016/s0168-3659(01)00306-6 CrossRefPubMed

Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307:58–62. https://doi.org/10.1126/science.1104819 CrossRefPubMed

Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48:7022–7032PubMed

Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653–664. https://doi.org/10.1038/nrclinonc.2010.139 CrossRefPubMedPubMedCentral

Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR (2002) Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 20:1826–1831. https://doi.org/10.1200/JCO.2002.07.082 CrossRefPubMed

Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape Immunology 121:1–14. https://doi.org/10.1111/j.1365-2567.2007.02587.x CrossRefPubMedPubMedCentral

Kim JY et al (2009) The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation Epigenetics 4:313–321CrossRefPubMed

Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161:175–187. https://doi.org/10.1016/j.jconrel.2011.09.063 CrossRefPubMed

Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392PubMed

McDonald DM, Thurston G, Baluk P (1999) Endothelial gaps as sites for plasma leakage in inflammation Microcirculation 6:7–22. https://doi.org/10.1080/713773924 CrossRefPubMed

Nagy JA, Chang SH, Dvorak AM, Dvorak HF (2009) Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100:865–869. https://doi.org/10.1038/sj.bjc.6604929 CrossRefPubMedPubMedCentral

Palazon A et al (2017) An HIF-1α/VEGF-A axis in cytotoxic T cells regulates tumor progression Cancer Cell 32:669–683.e665. https://doi.org/10.1016/j.ccell.2017.10.003 CrossRefPubMedPubMedCentral

Pasquali S et al (2015) Lymphatic and blood vasculature in primary cutaneous melanomas of the scalp and neck. Head Neck 37:1596–1602. https://doi.org/10.1002/hed.23801 CrossRefPubMed

Simonetti O et al (2013) Microvessel density and VEGF, HIF-1α expression in primary oral melanoma: correlation with prognosis. Oral Dis 19:620–627. https://doi.org/10.1111/odi.12048 CrossRefPubMed

Stirland DL, Nichols JW, Miura S, Bae YH (2013) Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release 172:1045–1064. https://doi.org/10.1016/j.jconrel.2013.09.026 CrossRefPubMedPubMedCentral

Stylianopoulos T, Jain RK (2013) Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A 110:18632–18637. https://doi.org/10.1073/pnas.1318415110 CrossRefPubMedPubMedCentral

Stylianopoulos T, Jain RK (2015) Design considerations for nanotherapeutics in oncology Nanomedicine 11:1893–1907. https://doi.org/10.1016/j.nano.2015.07.015 CrossRefPubMed

Taniguchi M, Seino K, Nakayama T (2003) The NKT cell system: bridging innate and acquired immunity. Nat Immunol 4:1164–1165. https://doi.org/10.1038/ni1203-1164 CrossRefPubMed

Tuthill RJ, Reed RJ (2007) Failure of senescence in the dysplasia-melanoma sequence: demonstration using a tissue microarray and a revised paradigm for melanoma. Semin Oncol 34:467–475. https://doi.org/10.1053/j.seminoncol.2007.09.014 CrossRefPubMed

Vakoc BJ et al (2009) Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 15:1219–1223. https://doi.org/10.1038/nm.1971 CrossRefPubMedPubMedCentral

Wahl ML et al (2002) Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 1:617–628PubMed

Title: Melanoma tumour vasculature heterogeneity: from mice models to human
Authors: Vincent Pautu
Adélie Mellinger
Pauline Resnier
Elise Lepeltier
Ludovic Martin
Lise Boussemart
Franck Letournel
Catherine Passirani
Nicolas Clere
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2809-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Melanoma tumour vasculature heterogeneity: from mice models to human

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Effects of metabolic syndrome on the prevalence of prostate cancer: historical cohort study using the national health insurance service database

T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer

TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas

Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018)

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page